Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.
about
Respiratory Syncytial Virus Infection Rates with Limited Use of Palivizumab for Infants Born at 29 to 31+6/7 Weeks Gestational Age.Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Beyond binding: antibody effector functions in infectious diseases.Human respiratory syncytial virus and hospitalization in young children in Italy.
P2860
Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Consensus conference on the ap ...... atory syncytial virus disease.
@ast
Consensus conference on the ap ...... atory syncytial virus disease.
@en
type
label
Consensus conference on the ap ...... atory syncytial virus disease.
@ast
Consensus conference on the ap ...... atory syncytial virus disease.
@en
prefLabel
Consensus conference on the ap ...... atory syncytial virus disease.
@ast
Consensus conference on the ap ...... atory syncytial virus disease.
@en
P2093
P2860
P356
P1476
Consensus conference on the ap ...... atory syncytial virus disease.
@en
P2093
Alessandra Pugi
Carlo Dani
Francesca Bellini
Giampaolo Donzelli
Giovanni Vitali Rosati
Giuseppe Buonocore
Klaus Peter Biermann
Luisa Galli
Maria Carmela Leo
Maria Serenella Pignotti
P2860
P304
P356
10.1002/PPUL.23561
P577
2016-09-12T00:00:00Z